Turn Therapeutics Inc.

NASDAQ:TTRX

Biotechnology

Healthcare
$8.89 -2.79%

-$0.17 today

Market cap
$271.79M
Beta
2.77
P/E (TTM)
-45.0
EPS (TTM)
-$0.13
52W Low $2.57High $26.50

Volume 0.05M

Average 0.04M

TTRX EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Turn Therapeutics Inc.NASDAQ: TTRX

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA of -$956.52K in Q1 FY2026

Q1 FY2026 EBITDA was -$956.52K. Trailing-twelve-month EBITDA was -$3.79M.

Context

  • EBITDA grew in size in 1 of the last 2 fiscal years.
  • FY2025 was the largest annual figure in the 3 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 1 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -82.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$956.52K-426.2% QoQ
Last fiscal yearDec 2025
-$3.14M-82.5% YoY
LTMMar 2026
-$3.79M— YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter—+100.0%—
1 year-82.5%+100.0%+182.5 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(3.14M) USD
Year-over-year change
-82.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How TTRX compares with its peers on the latest reported figures

  • TTRX's LTM Mar 2026 EBITDA of -$3.79M is the 2nd highest of the 9 companies compared; the peer median is -$25.97M.
TTRX Competitors Peer median
EBITDA for TTRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AGENAgenus Inc.LTM Mar 2026$127.04M +256.7%—102.6%
TTRXTurn Therapeutics Inc.LTM Mar 2026-$3.79M ———
ANIXAnixa Biosciences, Inc.LTM Apr 2026-$10.1M +17.4%——
CGTXCognition Therapeutics, Inc.LTM Mar 2026-$19.31M +41.5%——
GLSIGreenwich LifeSciences, Inc.LTM Mar 2026-$21.76M -35.5%——
HURATuHURA Biosciences, Inc.LTM Mar 2026-$30.19M -68.1%——
IKTInhibikase Therapeutics, Inc.LTM Mar 2026-$53.92M -39.7%——
SEERSeer, Inc.LTM Mar 2026-$64.35M +18.9%—427.9%
IRDOpus Genetics, Inc.LTM Mar 2026-$104.73M -226.0%—874.0%
Peer median (excluding TTRX) -$25.97M-9.0%—427.9%

Competitors are the stored peer set for TTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000
Cost of Revenue000
Gross Profit000
Gross Margin———
Research & Development7.5K245.96K265.57K
Selling, General & Admin2.3M1.55M5.59M
Operating Expenses2.31M1.8M5.86M
Depreciation & Amortization43.92K47.48K52.75K
EBITDA(2.25M)(1.72M)(3.14M)
EBITDA Margin———
Operating Income(2.31M)(1.8M)(5.86M)
Operating Margin———
Interest Income15.88K28.71K29.58K
Interest Expense000
Other Income / Expenses15.88K28.71K2.66M
Income Before Tax(2.29M)(1.77M)(3.19M)
Pre-Tax Margin———
Income Tax Expense000
Net Income(2.29M)(1.77M)(3.19M)
Net Margin———
EPS (Basic)(0.17)(0.13)(0.23)
EPS (Diluted)(0.17)(0.13)(0.23)
Weighted Avg Shares13.25M13.42M13.74M
Weighted Avg Shares (Diluted)13.25M13.42M13.74M

Turn Therapeutics Inc.

NASDAQ:TTRX

Intrinsic Alpha fair value

Locked

Current Price

$8.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.